Amersham Little Help to GE Healthcare in This Down Market

As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. But more so than the other two, GE Healthcare focuses on the development of new imaging agents, owing to its acquisition of Amersham in late 2003. Ant that integration has been admittedly slow.

As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. Siemens AG saw declining orders for imaging equipment in the US; Royal Philips Electronics NV experienced a 6% reduction in new order revenue in the fourth quarter, "largely if not totally driven by North America"; and GE Healthcare , a division of General Electric Co., reported that domestic order revenue was down nearly 30% in the quarter. As reported in The Gray Sheet, those cautionary comments "closely coincided with the release of multiple reports detailing hospitals’ reluctance to fund expensive capital projects." (See "Diagnostics Imaging Sector Hit By Hospitals' Dwindling Access to Capital," The Gray Sheet, February 2, 2009 Also see "Diagnostics Imaging Sector Hit By Hospitals’ Dwindling Access To Capital" - Medtech Insight, 2 February, 2009..)

But the problem for GE may lie deeper than a fall-off in instrument placements and downward pressures on reimbursement over all. More so than the other two, in addition to...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.